RFA-AG-25-026: Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 7, 2024.
From the official notice on Grants.gov, last changed August 12, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$675,456
- Typical project length4.5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-AG-25-026 were run by National Institute on Aging (NIA, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-25-026 in the NIH Guide.
Key dates
| Posted | August 12, 2024 |
|---|---|
| Deadline | November 7, 2024 |
| Archived by Grants.gov | December 13, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this Notice of Funding Opportunity (NOFO) is to support research to investigate mitochondrial-nuclear communication in the context of neurobiology and Alzheimer's disease and AD-related dementias (AD/ADRD). This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. This has the potential to serve as the foundation for the development of future AD/ADRD therapies that specifically target mitochondrial function as well as shed light on the role that mitochondria play in aging and neurodegeneration.
Funded under RFA-AG-25-026 so far
NIH funded 6 projects under RFA-AG-25-026 in fiscal 2025 to 2026, at 6 institutions. The median yearly award was $675,456.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A druggable mito-nuclear feedback mechanism that preserves mitochondrial and synaptic function in old-age | The Scripps Research Institute | 2026 | $857,190 |
| Dissecting the role of Tau-induced changes of SUMO and succinylCoA conjugation in mitochondrial-nuclear anterograde and retrograde signaling in FTD | Columbia University Health Sciences | 2026 | $457,159 |
| tRNA modifications regulating mitochondrial function and the mitochondrial proteome in AD/ADRD | Boston University Medical Campus | 2026 | $750,770 |
| Complex III-derived reactive oxygen species in mitochondrial-nuclear crosstalk in Alzheimer's disease and related dementias | Weill Medical Coll of Cornell Univ | 2026 | $754,382 |
| Mitochondria-Nuclear Communication via Lactylation in Alzheimer’s Disease | University of Kansas Medical Center | 2026 | $555,501 |
| Genetic dissection of mitonuclear interactions in aging and neurodegenerative disease | Broad Institute, Inc. | 2026 | $610,836 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-25-026 still open?
No. It closed on November 7, 2024.
Who can apply for Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed)?
Closed November 7, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AG-25-026?
NIH RePORTER lists 6 projects funded under RFA-AG-25-026 in fiscal 2025 to 2026, at 6 institutions. The most were at The Scripps Research Institute, Columbia University Health Sciences, Boston University Medical Campus.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)